Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients with Progranulin Gene Haploinsufficiency:A Randomized Clinical Trial

In: Ljubenkov , P A , Edwards , L , Iaccarino , L , La Joie , R , Rojas , J C , Koestler , M , Harris , B , Boeve , B F , Borroni , B , Van Swieten , J C , Grossman , M , Pasquier , F , Frisoni , G B , Mummery , C J , Vandenberghe , R , Le Ber , I , Hannequin , D , McGinnis , S M , Auriacombe , S , Onofrj , M , Goodman , I J , Riordan , H J , Wisniewski , G , Hesterman , J , Marek , K , Haynes , B A , Patzke , H , Koenig , G , Hilt , D , Moebius , H & Boxer , A L 2021 , ' Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients with Progranulin Gene Haploinsufficiency : A Randomized Clinical Trial ' , JAMA network open , vol. 4 , no. 9 , 25584 . https://doi.org/10.1001/jamanetworkopen.2021.25584

Abstract

Importance: Histone deacetylase inhibitors have been repeatedly shown to elevate progranulin levels in preclinical models. This report describes the first randomized clinical trial of a histone deacetylase inhibitor in frontotemporal dementia (FTD) resulting from progranulin (GRN) gene variations. Objective: To characterize the safety, tolerability, plasma pharmacokinetics, and pharmacodynamic effects of oral FRM-0334 on plasma progranulin and other exploratory biomarkers, including fluorodeoxyglucose (FDG)-positron emission tomography (PET), in individuals with GRN haploinsufficiency. Design, Setting, and Participants: In this randomized, double-blind, placebo-controlled, dose-escalating, phase 2a safety, tolerability, and pharmacodynamic clinical study, 2 doses of a histone deacetylase inhibitor (FRM-0334) were administered to participants with prodromal to moderate FTD with granulin variations. Participants were recruited from January 13, 2015, to April 13, 2016. The study included 27 participants with prodromal (n = 8) or mild-to-moderate symptoms of FTD (n = 19) and heterozygous pathogenic variations in GRN and was conducted at multiple centers in North America, the UK, and the European Union. Data were analyzed from June 9, 2019, to May 13, 2021. Interventions: Daily oral placebo (n = 5), 300 mg of FRM-0334 (n = 11), or 500 mg of FRM-0334 (n = 11) was administered for 28 days. Main Outcomes and Measures: Primary outcomes were safety and tolerability of FRM-0334 and its peripheral pharmacodynamic effect on plasma progranulin. Secondary outcomes were the plasma pharmacokinetic profile of FRM-0334 and its pharmacodynamic effect on cerebrospinal fluid progranulin. Exploratory outcomes were FDG-PET, FTD clinical severity, and cerebrospinal fluid biomarkers (neurofilament light chain [NfL], amyloid β 1-42, phosphorylated tau 181, and total tau [t-tau]). Results: A total of 27 participants (mean [SD] age, 56.6 [10.5] years; 16 women [59.3%]; 26 White participants [96.3%]) with GRN variations were randomized and ...